Complete Histologic Response of Regionally Metastatic Melanoma Treated with Intralesional Interleukin 2, Topical Retinoid and Imiquimod

Main Article Content

William Schaffenburg
Joshua Davis
Nicholas Logemann
Meagan Simpson


Melanoma, Interleukin 2


Abstract not available.


1. Shi VY, Tran K, Patel F, et al. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol. 2015 Oct;73(4):645-54. doi: 10.1016/j.jaad.2015.06.060. Epub 2015 Aug 7.

2. Miki Garcia M, Ono Y, Martinez S, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream Melanoma Research. 21(3):235–243, JUNE 2011 DOI: 10.1097/CMR.0b013e328345e95e,
PMID: 21464773

3. Green DS, Bodman-Smith AG, Fischer MD. “Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma” BJ Derm, 2007 Feb; 156(2): 337-345. doi:

4. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2010(12):180–190.